Literature DB >> 407312

Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta).

E L Stephen, M L Sammons, W L Pannier, S Baron, R O Spertzel, H B Levy.   

Abstract

Rhesus monkeys (Macaca mulatta) treated with a newly developed nuclease-resistant complex of polyriboinosinic-polyribocytidylic acid, poly-L-lysine, and carboxymethylcellulose [poly (ICLC)] did not die after challenge with virulent Asibi strain yellow fever (YF) virus. The strain of virus is sensitive to the effects of interferon in vitro and is lethal for rhesus monkeys four to six days after subcutaneous administration of 1,000 plaque-forming units of the virus. The mortality rate was reduced in monkeys initially treated 8 hr before or after inoculation of virus but was unchanged in monkeys initially treated 24 hr after challenge. Treated monkeys developed neutralizing antibody to YF virus. The successful treatment of yellow fever in a primate model with use of poly (ICLC) suggests a meaningful role for the interferon system in the host defense against this viral infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 407312     DOI: 10.1093/infdis/136.1.122

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Enhancement of the immunogenicity of phase I antigen of Coxiella burnetii.

Authors:  R F Wachter; G P Briggs; C E Pedersen
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

Review 3.  Molecular pathogenesis of viral hemorrhagic fever.

Authors:  Christopher F Basler
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

4.  Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine.

Authors:  D G Harrington; C L Crabbs; D E Hilmas; J R Brown; G A Higbee; F E Cole; H B Levy
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

Review 5.  Immunological features underlying viral hemorrhagic fevers.

Authors:  Ilhem Messaoudi; Christopher F Basler
Journal:  Curr Opin Immunol       Date:  2015-07-07       Impact factor: 7.486

6.  Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

Authors:  J J Kirsi; J A North; P A McKernan; B K Murray; P G Canonico; J W Huggins; P C Srivastava; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

7.  Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.

Authors:  M Kende; H W Lupton; W L Rill; P Gibbs; H B Levy; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

8.  Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.

Authors:  J P Wong; E G Saravolac; D Sabuda; H B Levy; M Kende
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.

Authors:  M Kende; H W Lupton; W L Rill; H B Levy; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Present status of yellow fever: memorandum from a PAHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.